HCM
ITCI

Highbridge Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Highbridge Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-142,280
Closed -$18.8M – 322
2025
Q1 		$18.8M Buy
+142,280
New +$17.7M 0.76% 42
2017
Q2 		– Sell
-49,407
Closed -$803K – 1676
2017
Q1 		$803K Buy
49,407
+38,425
+350% +$556K 0.01% 697
2016
Q4 		$166K Buy
+10,982
New +$155K ﹤0.01% 1158
2016
Q2 		– Sell
-8,676
Closed -$241K – 1811
2016
Q1 		$241K Buy
+8,676
New +$289K ﹤0.01% 1262
2015
Q4 		– Sell
-254,176
Closed -$10.2M – 1867
2015
Q3 		$10.2M Buy
+254,176
New +$8.29M 0.16% 178

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highbridge Capital Management's ITCI Position: Q2 2025 in Review

Highbridge Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 142,280 shares — an estimated $18.8M sold.

Highbridge Capital Management first reported a position in ITCI in Q3 2015 and held it in 5 quarters. The position peaked at $18.8M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Highbridge Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 142,280 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.8M.
  • Highbridge Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 5 quarters.
  • Highbridge Capital Management's Intra-Cellular Therapies Inc. position peaked at $18.8M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Highbridge Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.